Navigation Links
Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
Date:11/27/2012

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy".  The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and followed by questions and answers session from the audience.  Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug candidates.  The discussion is moderated by Dr. Rosemary Mazanet and participants include Dr. David Scheinberg, Chairman, and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center, Dr. Joseph Jurcic, Associate Attending Physician at Sloan-Kettering's Department of Leukemia and Dr. Steven Larson, Vice Chair for Research, Department of Radiology at Sloan Kettering. 

The focus of the webinar is the use of alpha radioimmunotherapy in clinical trials and preclinical models.  Dr. Scheinberg, who originated the idea of alpha immunotherapy, will discuss theoretical underpinnings of the approach and results of his preclinical experiments.  Dr. Jurcic is currently treating acute myeloid leukemia (AML) patients in clinical trials with alpha immunotherapy drug candidates and he will present his experience and results.  As a participant in clinical trials from the nuclear medicine side, Dr. Larson will provide a first-hand account on the ease of use and requirements for alpha immunotherapy.  All participants will also offer their views on the future prospects of drugs based on this platform technology. The panel discussion to be broadcast on November 30 at 3:00 PM Eastern Time, questions for participants may be submitted via apharma@actiniumpharmaceuticals.com or by phone, the details for which are as below:

Phone number: +1 (213) 493-0614
Access Code: 157-776-237

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/29/2017)... Orion, Michigan (PRWEB) , ... April 29, 2017 ... ... signs of fertility and infertility. These methods observe the naturally occurring signs ... in intercourse during the most fertile time. , Natural family planning and ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission ... Home Care Association of America (HCAOA). This agreement allows HCAOA members to receive ... well as discounts on Accreditation University (AU) educational resources that help prepare HCAOA ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield ... credit rating of “A” and its outlook as “stable.” At the same time, the ... have fallen in recent years, dip below “capital adequacy” thresholds required for its strong ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):